Explore peer-reviewed research articles, clinical trials, and molecular pathways in inflammatory diseases
Explore the groundbreaking phase 1 dose-escalation study of linclatamig, a LY6G6D×CD3 T cell-engaging bispecific antibody for colorectal cancer treatment.